For the millions of people living with multiple sclerosis, the central problem is a familiar and frustrating one. The immune system attacks the protective myelin sheath around nerves, leading to progressive disability. Existing therapies can slow the attack, but they largely cannot repair the damage already done. A small, preclinical biotech in Oklahoma City is now betting that a specific estrogen receptor, long studied in academic labs, could be the key to changing that equation [Cadenza Bio].
Cadenza Bio is developing CAD-1, an oral, brain-penetrant small molecule designed to activate estrogen receptor beta (ERβ). The company's thesis is that selectively targeting this receptor can do two things: modulate the inflammatory response driving the disease and, more ambitiously, promote the regeneration of lost myelin. This dual mechanism aims to move treatment beyond mere symptom management toward functional restoration, a goal that has remained stubbornly out of reach for most MS therapies [Cadenza Bio] [ScienceDaily, October 2025].
The Academic Genesis
The science behind Cadenza did not originate in a venture-backed lab. It emerged from a years-long collaboration between two academic powerhouses. Medicinal chemist John Katzenellenbogen at the University of Illinois Urbana-Champaign developed the novel chloroindazole analog compounds. Neuroscientist Seema Tiwari-Woodruff at the University of California, Riverside, then tested them in preclinical models of MS [Cadenza Bio].
Their peer-reviewed work, published in Scientific Reports, showed these synthetic ERβ ligands could reduce inflammation, restore myelin-producing cells, and improve visual pathway function in animal models [Cadenza Bio Announces Peer-Reviewed Study...]. This foundational research, partially funded by the National Multiple Sclerosis Society's Fast Forward program, provided the evidence that a non-steroidal, highly selective approach could have therapeutic potential. Cadenza Bio was formed in 2022 to license and advance this technology from the lab to the clinic [Cadenza Bio].
The Team and the Seed
Cadenza is led by co-founders Carol Curtis, Ph.D., as CEO, and Elaine Hamm, Ph.D., as COO. Hamm also runs Ascend BioVentures, a pharmaceutical accelerator, and the company was launched through a partnership between Ascend and Chicago's SmartHealth Catalyzer. To steer development, they brought on Dr. David E. Martin as Chief Development Officer, a veteran with over three decades of drug development experience [Cadenza Bio].
In December 2023, this team secured a $2.44 million seed round to begin the arduous journey from promising science to investigational new drug. The oversubscribed round was led by Plains Ventures and included a cohort of regional funds focused on life sciences: Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures [Cadenza Bio, December 2023].
The stated use of proceeds is focused on the critical, unglamorous work of early biotech: funding nonclinical safety and toxicology studies for CAD-1 and exploring secondary indications. The company has signaled interest in endometriosis, another inflammatory condition where ERβ modulation may play a role [Startup Intros].
| Role | Name | Background / Affiliation |
|---|---|---|
| Co-Founder & CEO | Carol Curtis, Ph.D. | Leads company strategy and operations. |
| Co-Founder & COO | Elaine Hamm, Ph.D. | Also founder/CEO of accelerator Ascend BioVentures. |
| Chief Development Officer | David E. Martin, Ph.D. | Over 30 years of drug development experience. |
| Scientific Founder | Seema Tiwari-Woodruff, Ph.D. | Professor of Biomedical Sciences, UC Riverside; MS pathology expert. |
| Scientific Founder | John A. Katzenellenbogen, Ph.D. | Professor of Chemistry, University of Illinois Urbana-Champaign. |
The Long Road to Proof
The ambition here is profound, but the path is littered with well-documented failure. Cadenza Bio operates in the highest-risk zone of biotech: preclinical development for a novel mechanism in a complex neurological disease. The company's entire valuation rests on animal model data that has not yet been translated to human biology. The next several years and tens of millions of dollars will be spent trying to bridge that gap, navigating Investigational New Drug (IND)-enabling studies and, eventually, Phase 1 clinical trials.
Competitive pressure is another reality. The market for MS therapies is crowded with entrenched players and next-generation candidates. Cadenza's potential advantage lies in its repair-focused mechanism, but it will need to demonstrate a safety and efficacy profile that justifies its use alongside or after existing immunomodulatory drugs. The company's most plausible answer to these risks is its focus on selectivity. By designing a non-steroidal compound that targets only ERβ, Cadenza aims to avoid the off-target effects and safety concerns associated with broader estrogenic activity, a hypothesis that now must be proven in rigorous toxicology studies [Cadenza Bio].
- The Translational Chasm. All of Cadenza's efficacy data comes from preclinical animal models. The leap to human safety and efficacy is the single greatest risk, requiring significant capital and time.
- The Selectivity Bet. The therapeutic premise hinges on the compound's "highly selective" action on ERβ. Any significant off-target activity could derail development on safety grounds.
- The Commercial Landscape. Even with clinical success, commercializing a new neurology drug requires deep expertise and resources far beyond Cadenza's current seed-stage footprint.
The Patient Population and Standard of Care
For patients with relapsing or progressive forms of multiple sclerosis, the current standard of care is a portfolio of disease-modifying therapies. These drugs, from injectable interferons to infused monoclonal antibodies, work primarily as immunomodulators. They are effective at reducing the frequency of relapses and slowing the accumulation of lesions visible on MRI. What they generally cannot do is repair damaged nerves or restore lost function. This leaves a persistent, unmet need for therapies that are not just defensive but regenerative. Cadenza Bio's entire bet is placed on addressing that specific gap in the treatment paradigm, aiming to offer something beyond stabilization for the nearly one million people living with MS in the United States alone.
The next twelve months for Cadenza will be measured in lab results, not patient outcomes. The key milestone is advancing CAD-1 through its IND-enabling studies. Success there would set the stage for a significantly larger financing round, likely a Series A, to fund initial human trials. For now, the company represents a classic, high-stakes biotech venture: a compelling scientific story, backed by peer-reviewed research and regional venture capital, now facing the formidable test of translation.
Sources
- [Cadenza Bio] Company Website | https://www.cadenza.bio/
- [Cadenza Bio, December 2023] Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing | https://www.cadenza.bio/news/cadenza-bio-inc-appoints-michael-a-panzara-md-mph-to-its-board-of-directors-1-hlczj
- [ScienceDaily, October 2025] Breakthrough compounds may reverse nerve damage caused by multiple sclerosis | https://www.sciencedaily.com/releases/2025/10/251011102259.htm
- [Cadenza Bio Announces Peer-Reviewed Study...] Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models | https://www.cadenza.bio/news
- [Startup Intros] Cadenza Bio: Funding, Team & Investors | Startup Intros | https://startupintros.com/orgs/cadenza-bio